▶ 調査レポート

世界の糖尿病性眼疾患治療市場 2028年:ドライアイ症候群、緑内障、眼アレルギー&感染症、糖尿病性網膜症、糖尿病性黄斑変性症、ブドウ膜炎、白内障、糖尿病性黄斑浮腫、その他

• 英文タイトル:Global Diabetes Associated Ophthalmic Treatment Market Insights, Forecast to 2028

Global Diabetes Associated Ophthalmic Treatment Market Insights, Forecast to 2028「世界の糖尿病性眼疾患治療市場 2028年:ドライアイ症候群、緑内障、眼アレルギー&感染症、糖尿病性網膜症、糖尿病性黄斑変性症、ブドウ膜炎、白内障、糖尿病性黄斑浮腫、その他」(市場規模、市場予測)調査レポートです。• レポートコード:QY2207C3487
• 出版社/出版日:QYResearch / 2022年7月11日
• レポート形態:英文、PDF、115ページ
• 納品方法:Eメール(納期:3日)
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥725,200 (USD4,900)▷ お問い合わせ
  Multi User¥1,087,800 (USD7,350)▷ お問い合わせ
  Enterprise License¥1,450,400 (USD9,800)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
新型コロナウイルス感染症のパンデミックにより、世界の糖尿病性眼疾患治療の市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx%で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に糖尿病性眼疾患治療の世界市場のxxx%を占める「ドライアイ症候群」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx%CAGRで成長すると予測されています。一方、「病院」セグメントは、この予測期間を通じてxxx%のCAGRに変更されます。
中国の糖尿病性眼疾患治療の市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの糖尿病性眼疾患治療市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx%であり、中国とヨーロッパはそれぞれxxx%とxxx%です。中国の割合は2028年にxxx%に達し、対象期間を通じてxxx%のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx%、xxx%、xxx%になる見通しです。ヨーロッパの糖尿病性眼疾患治療市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx%になる見通しです。

糖尿病性眼疾患治療のグローバル主要メーカーには、Alcon、Johnson & Johnson Services, Inc.、Bausch Health、F. Hoffmann-La Roche Ltd、Allergan、Bayer AG、Santen Pharmaceutical Co. Ltd.、Novartis AG、Pfizer, Inc.、Genentech, Inc.、Carl Zeiss Meditec、Lumenis、Ellex Medical Lasers Ltd.、IRIDEX Corp.、Topcon Corp.、Abbott Medical Optics、Quantelなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx%の市場シェアを占めています。

糖尿病性眼疾患治療市場は、種類と用途によって区分されます。世界の糖尿病性眼疾患治療市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年~2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。

【種類別セグメント】
ドライアイ症候群、緑内障、眼アレルギー&感染症、糖尿病性網膜症、糖尿病性黄斑変性症、ブドウ膜炎、白内障、糖尿病性黄斑浮腫、その他

【用途別セグメント】
病院、眼科センター、外来外科センター、その他

【掲載地域】
北米:アメリカ、カナダ
ヨーロッパ:ドイツ、フランス、イギリス、イタリア、ロシア
アジア太平洋:日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア
中南米:メキシコ、ブラジル、アルゼンチン
中東・アフリカ:トルコ、サウジアラビア、UAE

【目次(一部)】

・調査の範囲
- 糖尿病性眼疾患治療製品概要
- 種類別市場(ドライアイ症候群、緑内障、眼アレルギー&感染症、糖尿病性網膜症、糖尿病性黄斑変性症、ブドウ膜炎、白内障、糖尿病性黄斑浮腫、その他)
- 用途別市場(病院、眼科センター、外来外科センター、その他)
- 調査の目的
・エグゼクティブサマリー
- 世界の糖尿病性眼疾患治療販売量予測2017-2028
- 世界の糖尿病性眼疾患治療売上予測2017-2028
- 糖尿病性眼疾患治療の地域別販売量
- 糖尿病性眼疾患治療の地域別売上
- 北米市場
- ヨーロッパ市場
- アジア太平洋市場
- 中南米市場
- 中東・アフリカ市場
・メーカーの競争状況
- 主要メーカー別糖尿病性眼疾患治療販売量
- 主要メーカー別糖尿病性眼疾患治療売上
- 主要メーカー別糖尿病性眼疾患治療価格
- 競争状況の分析
- 企業M&A動向
・種類別市場規模(ドライアイ症候群、緑内障、眼アレルギー&感染症、糖尿病性網膜症、糖尿病性黄斑変性症、ブドウ膜炎、白内障、糖尿病性黄斑浮腫、その他)
- 糖尿病性眼疾患治療の種類別販売量
- 糖尿病性眼疾患治療の種類別売上
- 糖尿病性眼疾患治療の種類別価格
・用途別市場規模(病院、眼科センター、外来外科センター、その他)
- 糖尿病性眼疾患治療の用途別販売量
- 糖尿病性眼疾患治療の用途別売上
- 糖尿病性眼疾患治療の用途別価格
・北米市場
- 北米の糖尿病性眼疾患治療市場規模(種類別、用途別)
- 主要国別の糖尿病性眼疾患治療市場規模(アメリカ、カナダ)
・ヨーロッパ市場
- ヨーロッパの糖尿病性眼疾患治療市場規模(種類別、用途別)
- 主要国別の糖尿病性眼疾患治療市場規模(ドイツ、フランス、イギリス、イタリア、ロシア)
・アジア太平洋市場
- アジア太平洋の糖尿病性眼疾患治療市場規模(種類別、用途別)
- 主要国別の糖尿病性眼疾患治療市場規模(日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア)
・中南米市場
- 中南米の糖尿病性眼疾患治療市場規模(種類別、用途別)
- 主要国別の糖尿病性眼疾患治療市場規模(メキシコ、ブラジル、アルゼンチン)
・中東・アフリカ市場
- 中東・アフリカの糖尿病性眼疾患治療市場規模(種類別、用途別)
- 主要国別の糖尿病性眼疾患治療市場規模(トルコ、サウジアラビア)
・企業情報
Alcon、Johnson & Johnson Services, Inc.、Bausch Health、F. Hoffmann-La Roche Ltd、Allergan、Bayer AG、Santen Pharmaceutical Co. Ltd.、Novartis AG、Pfizer, Inc.、Genentech, Inc.、Carl Zeiss Meditec、Lumenis、Ellex Medical Lasers Ltd.、IRIDEX Corp.、Topcon Corp.、Abbott Medical Optics、Quantel
・産業チェーン及び販売チャネル分析
- 糖尿病性眼疾患治療の産業チェーン分析
- 糖尿病性眼疾患治療の原材料
- 糖尿病性眼疾患治療の生産プロセス
- 糖尿病性眼疾患治療の販売及びマーケティング
- 糖尿病性眼疾患治療の主要顧客
・マーケットドライバー、機会、課題、リスク要因分析
- 糖尿病性眼疾患治療の産業動向
- 糖尿病性眼疾患治療のマーケットドライバー
- 糖尿病性眼疾患治療の課題
- 糖尿病性眼疾患治療の阻害要因
・主な調査結果

Diabetic eye disease is a group of eye problems that can affect people with diabetes. These conditions include diabetic retinopathy, diabetic macular edema, cataracts, and glaucoma. An increase in the incidence of diabetes due to aging, obesity, and an unhealthy lifestyle is one of the factors contributing to the growth of the market for diabetes-associated ophthalmic.
Market Analysis and Insights: Global Diabetes Associated Ophthalmic Treatment Market
The global Diabetes Associated Ophthalmic Treatment market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, Dry Eye Syndrome accounting for % of the Diabetes Associated Ophthalmic Treatment global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospitals segment is altered to an % CAGR throughout this forecast period.
China Diabetes Associated Ophthalmic Treatment market size is valued at US$ million in 2021, while the North America and Europe Diabetes Associated Ophthalmic Treatment are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Diabetes Associated Ophthalmic Treatment landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Diabetes Associated Ophthalmic Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Diabetes Associated Ophthalmic Treatment market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Diabetes Associated Ophthalmic Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Diabetes Associated Ophthalmic Treatment market.
Global Diabetes Associated Ophthalmic Treatment Scope and Market Size
Diabetes Associated Ophthalmic Treatment market is segmented by players, region (country), by Type and by End User. Players, stakeholders, and other participants in the global Diabetes Associated Ophthalmic Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by End User for the period 2017-2028.
Segment by Type
Dry Eye Syndrome
Glaucoma
Eye Allergy & Infection
Diabetic Retinopathy
Diabetic associated Macular Degeneration
Uveitis
Cataract
Diabetic Macular Edema
Others
Segment by End User
Hospitals
Ophthalmic Centers
Ambulatory Surgical Centers
Others
By Company
Alcon
Johnson & Johnson Services, Inc.
Bausch Health
F. Hoffmann-La Roche Ltd
Allergan
Bayer AG
Santen Pharmaceutical Co. Ltd.
Novartis AG
Pfizer, Inc.
Genentech, Inc.
Carl Zeiss Meditec
Lumenis
Ellex Medical Lasers Ltd.
IRIDEX Corp.
Topcon Corp.
Abbott Medical Optics
Quantel
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

レポート目次

1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Diabetes Associated Ophthalmic Treatment Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Dry Eye Syndrome
1.2.3 Glaucoma
1.2.4 Eye Allergy & Infection
1.2.5 Diabetic Retinopathy
1.2.6 Diabetic associated Macular Degeneration
1.2.7 Uveitis
1.2.8 Cataract
1.2.9 Diabetic Macular Edema
1.2.10 Others
1.3 Market by End User
1.3.1 Global Diabetes Associated Ophthalmic Treatment Market Size Growth Rate by End User, 2017 VS 2021 VS 2028
1.3.2 Hospitals
1.3.3 Ophthalmic Centers
1.3.4 Ambulatory Surgical Centers
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Diabetes Associated Ophthalmic Treatment Market Perspective (2017-2028)
2.2 Diabetes Associated Ophthalmic Treatment Growth Trends by Region
2.2.1 Diabetes Associated Ophthalmic Treatment Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Diabetes Associated Ophthalmic Treatment Historic Market Size by Region (2017-2022)
2.2.3 Diabetes Associated Ophthalmic Treatment Forecasted Market Size by Region (2023-2028)
2.3 Diabetes Associated Ophthalmic Treatment Market Dynamics
2.3.1 Diabetes Associated Ophthalmic Treatment Industry Trends
2.3.2 Diabetes Associated Ophthalmic Treatment Market Drivers
2.3.3 Diabetes Associated Ophthalmic Treatment Market Challenges
2.3.4 Diabetes Associated Ophthalmic Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Diabetes Associated Ophthalmic Treatment Players by Revenue
3.1.1 Global Top Diabetes Associated Ophthalmic Treatment Players by Revenue (2017-2022)
3.1.2 Global Diabetes Associated Ophthalmic Treatment Revenue Market Share by Players (2017-2022)
3.2 Global Diabetes Associated Ophthalmic Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Diabetes Associated Ophthalmic Treatment Revenue
3.4 Global Diabetes Associated Ophthalmic Treatment Market Concentration Ratio
3.4.1 Global Diabetes Associated Ophthalmic Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Diabetes Associated Ophthalmic Treatment Revenue in 2021
3.5 Diabetes Associated Ophthalmic Treatment Key Players Head office and Area Served
3.6 Key Players Diabetes Associated Ophthalmic Treatment Product Solution and Service
3.7 Date of Enter into Diabetes Associated Ophthalmic Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Diabetes Associated Ophthalmic Treatment Breakdown Data by Type
4.1 Global Diabetes Associated Ophthalmic Treatment Historic Market Size by Type (2017-2022)
4.2 Global Diabetes Associated Ophthalmic Treatment Forecasted Market Size by Type (2023-2028)
5 Diabetes Associated Ophthalmic Treatment Breakdown Data by End User
5.1 Global Diabetes Associated Ophthalmic Treatment Historic Market Size by End User (2017-2022)
5.2 Global Diabetes Associated Ophthalmic Treatment Forecasted Market Size by End User (2023-2028)
6 North America
6.1 North America Diabetes Associated Ophthalmic Treatment Market Size (2017-2028)
6.2 North America Diabetes Associated Ophthalmic Treatment Market Size by Type
6.2.1 North America Diabetes Associated Ophthalmic Treatment Market Size by Type (2017-2022)
6.2.2 North America Diabetes Associated Ophthalmic Treatment Market Size by Type (2023-2028)
6.2.3 North America Diabetes Associated Ophthalmic Treatment Market Share by Type (2017-2028)
6.3 North America Diabetes Associated Ophthalmic Treatment Market Size by End User
6.3.1 North America Diabetes Associated Ophthalmic Treatment Market Size by End User (2017-2022)
6.3.2 North America Diabetes Associated Ophthalmic Treatment Market Size by End User (2023-2028)
6.3.3 North America Diabetes Associated Ophthalmic Treatment Market Share by End User (2017-2028)
6.4 North America Diabetes Associated Ophthalmic Treatment Market Size by Country
6.4.1 North America Diabetes Associated Ophthalmic Treatment Market Size by Country (2017-2022)
6.4.2 North America Diabetes Associated Ophthalmic Treatment Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Diabetes Associated Ophthalmic Treatment Market Size (2017-2028)
7.2 Europe Diabetes Associated Ophthalmic Treatment Market Size by Type
7.2.1 Europe Diabetes Associated Ophthalmic Treatment Market Size by Type (2017-2022)
7.2.2 Europe Diabetes Associated Ophthalmic Treatment Market Size by Type (2023-2028)
7.2.3 Europe Diabetes Associated Ophthalmic Treatment Market Share by Type (2017-2028)
7.3 Europe Diabetes Associated Ophthalmic Treatment Market Size by End User
7.3.1 Europe Diabetes Associated Ophthalmic Treatment Market Size by End User (2017-2022)
7.3.2 Europe Diabetes Associated Ophthalmic Treatment Market Size by End User (2023-2028)
7.3.3 Europe Diabetes Associated Ophthalmic Treatment Market Share by End User (2017-2028)
7.4 Europe Diabetes Associated Ophthalmic Treatment Market Size by Country
7.4.1 Europe Diabetes Associated Ophthalmic Treatment Market Size by Country (2017-2022)
7.4.2 Europe Diabetes Associated Ophthalmic Treatment Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Diabetes Associated Ophthalmic Treatment Market Size (2017-2028)
8.2 Asia-Pacific Diabetes Associated Ophthalmic Treatment Market Size by Type
8.2.1 Asia-Pacific Diabetes Associated Ophthalmic Treatment Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Diabetes Associated Ophthalmic Treatment Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Diabetes Associated Ophthalmic Treatment Market Share by Type (2017-2028)
8.3 Asia-Pacific Diabetes Associated Ophthalmic Treatment Market Size by End User
8.3.1 Asia-Pacific Diabetes Associated Ophthalmic Treatment Market Size by End User (2017-2022)
8.3.2 Asia-Pacific Diabetes Associated Ophthalmic Treatment Market Size by End User (2023-2028)
8.3.3 Asia-Pacific Diabetes Associated Ophthalmic Treatment Market Share by End User (2017-2028)
8.4 Asia-Pacific Diabetes Associated Ophthalmic Treatment Market Size by Region
8.4.1 Asia-Pacific Diabetes Associated Ophthalmic Treatment Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Diabetes Associated Ophthalmic Treatment Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Diabetes Associated Ophthalmic Treatment Market Size (2017-2028)
9.2 Latin America Diabetes Associated Ophthalmic Treatment Market Size by Type
9.2.1 Latin America Diabetes Associated Ophthalmic Treatment Market Size by Type (2017-2022)
9.2.2 Latin America Diabetes Associated Ophthalmic Treatment Market Size by Type (2023-2028)
9.2.3 Latin America Diabetes Associated Ophthalmic Treatment Market Share by Type (2017-2028)
9.3 Latin America Diabetes Associated Ophthalmic Treatment Market Size by End User
9.3.1 Latin America Diabetes Associated Ophthalmic Treatment Market Size by End User (2017-2022)
9.3.2 Latin America Diabetes Associated Ophthalmic Treatment Market Size by End User (2023-2028)
9.3.3 Latin America Diabetes Associated Ophthalmic Treatment Market Share by End User (2017-2028)
9.4 Latin America Diabetes Associated Ophthalmic Treatment Market Size by Country
9.4.1 Latin America Diabetes Associated Ophthalmic Treatment Market Size by Country (2017-2022)
9.4.2 Latin America Diabetes Associated Ophthalmic Treatment Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Diabetes Associated Ophthalmic Treatment Market Size (2017-2028)
10.2 Middle East & Africa Diabetes Associated Ophthalmic Treatment Market Size by Type
10.2.1 Middle East & Africa Diabetes Associated Ophthalmic Treatment Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Diabetes Associated Ophthalmic Treatment Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Diabetes Associated Ophthalmic Treatment Market Share by Type (2017-2028)
10.3 Middle East & Africa Diabetes Associated Ophthalmic Treatment Market Size by End User
10.3.1 Middle East & Africa Diabetes Associated Ophthalmic Treatment Market Size by End User (2017-2022)
10.3.2 Middle East & Africa Diabetes Associated Ophthalmic Treatment Market Size by End User (2023-2028)
10.3.3 Middle East & Africa Diabetes Associated Ophthalmic Treatment Market Share by End User (2017-2028)
10.4 Middle East & Africa Diabetes Associated Ophthalmic Treatment Market Size by Country
10.4.1 Middle East & Africa Diabetes Associated Ophthalmic Treatment Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Diabetes Associated Ophthalmic Treatment Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Alcon
11.1.1 Alcon Company Details
11.1.2 Alcon Business Overview
11.1.3 Alcon Diabetes Associated Ophthalmic Treatment Introduction
11.1.4 Alcon Revenue in Diabetes Associated Ophthalmic Treatment Business (2017-2022)
11.1.5 Alcon Recent Developments
11.2 Johnson & Johnson Services, Inc.
11.2.1 Johnson & Johnson Services, Inc. Company Details
11.2.2 Johnson & Johnson Services, Inc. Business Overview
11.2.3 Johnson & Johnson Services, Inc. Diabetes Associated Ophthalmic Treatment Introduction
11.2.4 Johnson & Johnson Services, Inc. Revenue in Diabetes Associated Ophthalmic Treatment Business (2017-2022)
11.2.5 Johnson & Johnson Services, Inc. Recent Developments
11.3 Bausch Health
11.3.1 Bausch Health Company Details
11.3.2 Bausch Health Business Overview
11.3.3 Bausch Health Diabetes Associated Ophthalmic Treatment Introduction
11.3.4 Bausch Health Revenue in Diabetes Associated Ophthalmic Treatment Business (2017-2022)
11.3.5 Bausch Health Recent Developments
11.4 F. Hoffmann-La Roche Ltd
11.4.1 F. Hoffmann-La Roche Ltd Company Details
11.4.2 F. Hoffmann-La Roche Ltd Business Overview
11.4.3 F. Hoffmann-La Roche Ltd Diabetes Associated Ophthalmic Treatment Introduction
11.4.4 F. Hoffmann-La Roche Ltd Revenue in Diabetes Associated Ophthalmic Treatment Business (2017-2022)
11.4.5 F. Hoffmann-La Roche Ltd Recent Developments
11.5 Allergan
11.5.1 Allergan Company Details
11.5.2 Allergan Business Overview
11.5.3 Allergan Diabetes Associated Ophthalmic Treatment Introduction
11.5.4 Allergan Revenue in Diabetes Associated Ophthalmic Treatment Business (2017-2022)
11.5.5 Allergan Recent Developments
11.6 Bayer AG
11.6.1 Bayer AG Company Details
11.6.2 Bayer AG Business Overview
11.6.3 Bayer AG Diabetes Associated Ophthalmic Treatment Introduction
11.6.4 Bayer AG Revenue in Diabetes Associated Ophthalmic Treatment Business (2017-2022)
11.6.5 Bayer AG Recent Developments
11.7 Santen Pharmaceutical Co. Ltd.
11.7.1 Santen Pharmaceutical Co. Ltd. Company Details
11.7.2 Santen Pharmaceutical Co. Ltd. Business Overview
11.7.3 Santen Pharmaceutical Co. Ltd. Diabetes Associated Ophthalmic Treatment Introduction
11.7.4 Santen Pharmaceutical Co. Ltd. Revenue in Diabetes Associated Ophthalmic Treatment Business (2017-2022)
11.7.5 Santen Pharmaceutical Co. Ltd. Recent Developments
11.8 Novartis AG
11.8.1 Novartis AG Company Details
11.8.2 Novartis AG Business Overview
11.8.3 Novartis AG Diabetes Associated Ophthalmic Treatment Introduction
11.8.4 Novartis AG Revenue in Diabetes Associated Ophthalmic Treatment Business (2017-2022)
11.8.5 Novartis AG Recent Developments
11.9 Pfizer, Inc.
11.9.1 Pfizer, Inc. Company Details
11.9.2 Pfizer, Inc. Business Overview
11.9.3 Pfizer, Inc. Diabetes Associated Ophthalmic Treatment Introduction
11.9.4 Pfizer, Inc. Revenue in Diabetes Associated Ophthalmic Treatment Business (2017-2022)
11.9.5 Pfizer, Inc. Recent Developments
11.10 Genentech, Inc.
11.10.1 Genentech, Inc. Company Details
11.10.2 Genentech, Inc. Business Overview
11.10.3 Genentech, Inc. Diabetes Associated Ophthalmic Treatment Introduction
11.10.4 Genentech, Inc. Revenue in Diabetes Associated Ophthalmic Treatment Business (2017-2022)
11.10.5 Genentech, Inc. Recent Developments
11.11 Carl Zeiss Meditec
11.11.1 Carl Zeiss Meditec Company Details
11.11.2 Carl Zeiss Meditec Business Overview
11.11.3 Carl Zeiss Meditec Diabetes Associated Ophthalmic Treatment Introduction
11.11.4 Carl Zeiss Meditec Revenue in Diabetes Associated Ophthalmic Treatment Business (2017-2022)
11.11.5 Carl Zeiss Meditec Recent Developments
11.12 Lumenis
11.12.1 Lumenis Company Details
11.12.2 Lumenis Business Overview
11.12.3 Lumenis Diabetes Associated Ophthalmic Treatment Introduction
11.12.4 Lumenis Revenue in Diabetes Associated Ophthalmic Treatment Business (2017-2022)
11.12.5 Lumenis Recent Developments
11.13 Ellex Medical Lasers Ltd.
11.13.1 Ellex Medical Lasers Ltd. Company Details
11.13.2 Ellex Medical Lasers Ltd. Business Overview
11.13.3 Ellex Medical Lasers Ltd. Diabetes Associated Ophthalmic Treatment Introduction
11.13.4 Ellex Medical Lasers Ltd. Revenue in Diabetes Associated Ophthalmic Treatment Business (2017-2022)
11.13.5 Ellex Medical Lasers Ltd. Recent Developments
11.14 IRIDEX Corp.
11.14.1 IRIDEX Corp. Company Details
11.14.2 IRIDEX Corp. Business Overview
11.14.3 IRIDEX Corp. Diabetes Associated Ophthalmic Treatment Introduction
11.14.4 IRIDEX Corp. Revenue in Diabetes Associated Ophthalmic Treatment Business (2017-2022)
11.14.5 IRIDEX Corp. Recent Developments
11.15 Topcon Corp.
11.15.1 Topcon Corp. Company Details
11.15.2 Topcon Corp. Business Overview
11.15.3 Topcon Corp. Diabetes Associated Ophthalmic Treatment Introduction
11.15.4 Topcon Corp. Revenue in Diabetes Associated Ophthalmic Treatment Business (2017-2022)
11.15.5 Topcon Corp. Recent Developments
11.16 Abbott Medical Optics
11.16.1 Abbott Medical Optics Company Details
11.16.2 Abbott Medical Optics Business Overview
11.16.3 Abbott Medical Optics Diabetes Associated Ophthalmic Treatment Introduction
11.16.4 Abbott Medical Optics Revenue in Diabetes Associated Ophthalmic Treatment Business (2017-2022)
11.16.5 Abbott Medical Optics Recent Developments
11.17 Quantel
11.17.1 Quantel Company Details
11.17.2 Quantel Business Overview
11.17.3 Quantel Diabetes Associated Ophthalmic Treatment Introduction
11.17.4 Quantel Revenue in Diabetes Associated Ophthalmic Treatment Business (2017-2022)
11.17.5 Quantel Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer